- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Health Bulletin 27/April/2022 - Video
Overview
Here are the top health stories for the day :
NMC denies permission to 3 Medical Colleges, 550 MBBS seats lost
Finding major deficiencies in three major medical institutes in Rajasthan, the National Medical Commission (NMC) has declined its permission for admitting students in the MBBS and PG medical courses offered in those colleges for the academic year 2021-2022.
This has resulted in loss of around 550 MBBS seats as the Apex medical regulator has withdrawn permission for 250 MBBS seats of Geetanjali Medical College and Hospital,150 MBBS seats of Pacific Institute of Medical Sciences, and 150 MBBS seats of American International Institute of Medical Sciences.
For more details, check out the full story on the link below:
NMC Denies Permission To 3 Medical Colleges, 550 MBBS Seats Lost
Coronavirus vaccine: DCGI grants emergency use nod to Covaxin, Corbevax, ZycovD for different age group of children
The Drugs Controller General of India (DCGI) on Tuesday approved three Covid vaccines for the restricted emergency use authorisation (EUA) for children of different age groups.
The DCGI gave the restricted emergency use authorisation to Bharat Biotech's Covaxin for children between the age of 6-12 years.
For more details, check out the full story on the link below:
NMC warns against circulation of fake allotment letters for MBBS admission, files FIR
Taking action against fake allotment letters for MBBS admission, the National Medical Commission (NMC) has filed a First Information Report in the matter.
Apart from filing the FIR, the apex medical regulatory body has further issued a Public Notice in this regard and warned the aspirants that NMC in not involved in offering admissions to medical courses.
For more details, check out the full story on the link below:
NMC Warns Against Circulation Of Fake Allotment Letters For MBBS Admission, Files FIR
1,204 fresh Covid cases, one more death in Delhi
According to government's health bulletin, Delhi has reported 1,204 new Covid-19 cases in the last 24 hours. Now, the city's total active cases are 4,508. It is for the fifth continuous day that the national capital has reported over 1,000 cases.
The national capital has witnessed a dip in the Covid positivity rate- 4.64%, as per the Delhi health bulletin.
In the last 24 hours, one Covid death was also reported in Delhi. With a fatality rate of 1.39%, the total tally of deaths caused in the national capital due to the virus now stands at 26,169.
For more news, check out the medical dialogues site:
GSK launches once daily, single inhaler-triple therapy for COPD patients
GlaxoSmithKline Pharmaceuticals Limited has recently launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime.
The launch follows the product's approval by the Drugs Controller General of India (DCGI) for use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.
For more details, check out the full story on the link below:
GSK Launches Single Inhaler-Triple Therapy Trelegy Ellipta To Treat COPD In India
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)